ENDRA Life Sciences (NASDAQ:NDRA) reported quarterly losses of $(2.10) per share which missed the analyst consensus estimate of $(1.95) by 7.69 percent. This is a 77.99 percent increase over losses of $(9.54) per share from the same period last year.